Clinical Trial Update: A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating trametinib with erlotinib in EGFR-mutant lung adenocarcinomas with acquired resistance to erlotinib has completed with results post…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Adenocarcinoma

Drugs mentioned

• ERLOTINIB (Erlotinib)
• Trametinib (trametinib)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lung Adenocarcinoma, Lung Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2022-02-08